Therapeutic Vaccines for Tuberculosis: An Overview
Tuberculosis (TB), caused by Mycobacterium tuberculosis is the world’s deadliest bacterial infection, resulting in more than 1.4 million deaths annually. The emergence of drug-resistance to first-line antibiotic therapy poses a threat to successful treatment, and novel therapeutic options are requir...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.878471/full |
| _version_ | 1811239423208062976 |
|---|---|
| author | Rania Bouzeyen Babak Javid |
| author_facet | Rania Bouzeyen Babak Javid |
| author_sort | Rania Bouzeyen |
| collection | DOAJ |
| description | Tuberculosis (TB), caused by Mycobacterium tuberculosis is the world’s deadliest bacterial infection, resulting in more than 1.4 million deaths annually. The emergence of drug-resistance to first-line antibiotic therapy poses a threat to successful treatment, and novel therapeutic options are required, particularly for drug-resistant tuberculosis. One modality emerging for TB treatment is therapeutic vaccination. As opposed to preventative vaccination – the aim of which is to prevent getting infected by M. tuberculosis or developing active tuberculosis, the purpose of therapeutic vaccination is as adjunctive treatment of TB or to prevent relapse following cure. Several candidate therapeutic vaccines, using killed whole-cell or live attenuated mycobacteria, mycobacterial fragments and viral vectored vaccines are in current clinical trials. Other modes of passive immunization, including monoclonal antibodies directed against M. tuberculosis antigens are in various pre-clinical stages of development. Here, we will discuss these various therapeutics and their proposed mechanisms of action. Although the full clinical utility of therapeutic vaccination for the treatment of tuberculosis is yet to be established, they hold potential as useful adjunct therapies. |
| first_indexed | 2024-04-12T13:00:40Z |
| format | Article |
| id | doaj.art-ce9e1c56ac1a4f44829f1f0cf4c53cf3 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T13:00:40Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-ce9e1c56ac1a4f44829f1f0cf4c53cf32022-12-22T03:32:11ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-06-011310.3389/fimmu.2022.878471878471Therapeutic Vaccines for Tuberculosis: An OverviewRania BouzeyenBabak JavidTuberculosis (TB), caused by Mycobacterium tuberculosis is the world’s deadliest bacterial infection, resulting in more than 1.4 million deaths annually. The emergence of drug-resistance to first-line antibiotic therapy poses a threat to successful treatment, and novel therapeutic options are required, particularly for drug-resistant tuberculosis. One modality emerging for TB treatment is therapeutic vaccination. As opposed to preventative vaccination – the aim of which is to prevent getting infected by M. tuberculosis or developing active tuberculosis, the purpose of therapeutic vaccination is as adjunctive treatment of TB or to prevent relapse following cure. Several candidate therapeutic vaccines, using killed whole-cell or live attenuated mycobacteria, mycobacterial fragments and viral vectored vaccines are in current clinical trials. Other modes of passive immunization, including monoclonal antibodies directed against M. tuberculosis antigens are in various pre-clinical stages of development. Here, we will discuss these various therapeutics and their proposed mechanisms of action. Although the full clinical utility of therapeutic vaccination for the treatment of tuberculosis is yet to be established, they hold potential as useful adjunct therapies.https://www.frontiersin.org/articles/10.3389/fimmu.2022.878471/fulltuberculosismycobacteriumtherapeutic vaccinesprevention of recurrencemonoclonal antibodymRNA vaccine |
| spellingShingle | Rania Bouzeyen Babak Javid Therapeutic Vaccines for Tuberculosis: An Overview Frontiers in Immunology tuberculosis mycobacterium therapeutic vaccines prevention of recurrence monoclonal antibody mRNA vaccine |
| title | Therapeutic Vaccines for Tuberculosis: An Overview |
| title_full | Therapeutic Vaccines for Tuberculosis: An Overview |
| title_fullStr | Therapeutic Vaccines for Tuberculosis: An Overview |
| title_full_unstemmed | Therapeutic Vaccines for Tuberculosis: An Overview |
| title_short | Therapeutic Vaccines for Tuberculosis: An Overview |
| title_sort | therapeutic vaccines for tuberculosis an overview |
| topic | tuberculosis mycobacterium therapeutic vaccines prevention of recurrence monoclonal antibody mRNA vaccine |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.878471/full |
| work_keys_str_mv | AT raniabouzeyen therapeuticvaccinesfortuberculosisanoverview AT babakjavid therapeuticvaccinesfortuberculosisanoverview |